Moneycontrol PRO
Upcoming Event:Attend Algo Convention Live, 2 Days & 12+ Speakers at best offer Rs.999/-, exclusive for Moneycontrol Pro subscribers. Register now!
you are here: HomeNewsTrends

Serum Institute of India CEO Adar Poonawala hits back at critics: Key Highlights of The Times interview

Rejecting the charges of profiteering from the vaccine, Serum Institute of India CEO Adar Poonawala said that it is “totally incorrect” and added that Covishield will still be “the most affordable vaccine on the planet” even at a higher price. "

May 02, 2021 / 09:45 AM IST
Serum Institute India (SII) CEO Adar Poonawalla (Image: Twitter/@adarpoonawalla)

Serum Institute India (SII) CEO Adar Poonawalla (Image: Twitter/@adarpoonawalla)

After receiving 'Y' category security, Adar Poonawala - the chief of Serum Institute of India (SII) - spoke to a London newspaper about receiving threat calls from India's most powerful men and politicians including “chief ministers…, heads of business conglomerates and others”.

Threats is an understatement,” Mr Poonawalla told The Times of London. “The level of expectation and aggression is really unprecedented. It’s overwhelming. Everyone feels they should get the vaccine. They can’t understand why anyone else should get it before them,” he said.

“They are saying if you don’t give us the vaccine it’s not going to be good… It’s not foul language. It’s the tone. It’s the implication of what they might do if I don’t comply. It’s taking control. It’s coming over and basically surrounding the place and not letting us do anything unless we give in to their demands,” Poonawalla added.

Poonawala flew to London to be with his wife and children before the UK barred travellers from India on April 23.

“I’m staying here an extended time because I don’t want to go back to that situation,” he added. “Everything falls on my shoulders, but I can’t do it alone. … I don’t want to be in a situation where you are just trying to do your job, and just because you can’t supply the needs of X, Y or Z you really don’t want to guess what they are going to do.”


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
The interview took social media by storm. After the interview, the CEO of the vaccine maker company tweeted about an "excellent meeting" with all the partners and stakeholders. "Meanwhile, pleased to state that COVISHIELD’s production is in full swing in Pune. I look forward to reviewing operations upon my return in a few days,” he added.

According to the newspaper, by the time the Oxford/AstraZeneca vaccine was approved in January, the SII increased its annual production capacity from 1.5 to 2.5 billion doses at a cost of USD 800 million, and stockpiled 50 million doses of Covishield.

The company began exporting to 68 countries, including Britain, as India seemed to have been over the worse, until the situation worsened in recent weeks.

Rejecting the charges of profiteering from the vaccine, Poonawala said that it is “totally incorrect” and added that Covishield will still be “the most affordable vaccine on the planet” even at a higher price. "

"We have done the best we can without cutting corners or doing anything wrong or profiteering. I’ll wait for history to judge,” he said.

“I’ve always had this sense of responsibility to India and the world because of the vaccines we were making, but never have we made a vaccine so needed in terms of saving lives,” he added.

The price of the Covishield vaccine supplied to the state governments will be reduced to Rs 300 per dose with immediate effect, Poonawala said on April 28. SII earlier priced Covishield at Rs 400 per dose for the state governments and Rs 600 for the private hospitals.

Answering who is responsible for India's second wave of infections that has gripped the country, Poonawala said that “If I give you the right answer, or any answer, my head would be chopped off… I can’t comment on the elections or Kumbh Mela. It’s too sensitive… I don’t think even God could have forecast it was going to get this bad.”

[Inputs from PTI]

Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

Moneycontrol News
first published: May 2, 2021 09:45 am
ISO 27001 - BSI Assurance Mark